Johnson & Johnson to Host Business Review Highlighting Pharmaceuticals

NEW BRUNSWICK, N.J. October 13, 2021 - Johnson & Johnson will hold a Business Review for the investment community on Thursday, November 18, 2021, in which company leaders will share a detailed review of its Pharmaceuticals business, differentiated strategy and robust pipeline, and long-term growth outlook.The Business Review will include:- Comprehensive Pipeline Overviews for our Six Therapeutic Areas and Data Sciences available on a virtual platform beginning at 9:00 a.m. ET on November 17, 2021- Live General Session on November 18, 2021 beginning at 8:30 a.m. ET and ending at approximately 1:00 p.m. ET, featuring:Enterprise remarks from current CEO and Chairman, Alex Gorsky, incoming CEO Joaquin Duato and CFO Joe WolkInsights into Janssen’s transformational innovation engine and commercial capabilities fueling both short and long-term growth delivered by Jennifer Taubert, Executive Vice President, Worldwide Chairman and Mathai Mammen, Global Head, Janssen Research & Development Spotlight presentations highlighting key product opportunities across the Company’s current and future pipelineQ&A sessions with leaders from the Company’s Executive Committee, and Janssen Research & Development, Commercial, and Supply Chain organizationsThose planning to attend the event can register at www.investor.jnj.com starting November 1, 2021. A replay and supporting content will be posted by the end of the day on November 18, 2021.NOTE TO INVESTORS CONCERNING FORWARD-LO...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news